European Neurologists Expect Significant Increases In The Use Of Both Tysabri And Extavia In Their Multiple Sclerosis Patients

Stuart SchlossmanMS Drug Therapies, Multiple Sclerosis, Tysabri

December 28, 2010


BioTrends Research Group, Inc. finds that while neurologists in the EU tend to prescribe the established interferon betas as their first line disease modifying agents (DMAs) for the treatment of multiple sclerosis (MS) patients, they are most satisfied with Biogen/Elan’sTysabri. Prescribing of both Tysabri and Novartis’s recently launched DMA, Extavia, is anticipated to increase over the next six months with Bayer’s Betaferon suffering the most in terms of market share loss. Despite these expected changes, neurologists clearly associate most of the DMAs with a certain MS patient type and their reported prescribing reflects these preference patterns.


CONTINUE READING

****************************************************************

If you find our information valuable, 
please donate by clicking here 
— all contributions are tax deductible —
****************************************************************
Providing You with ‘MS Views and News’is what we do
Keep Informed and uptodate with information concerning
 Multiple Sclerosis when registered at
the MS Views and News  website.
****************************************************************
Disclaimer:  ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews